In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition

Fania Szlam; Kenichi A. Tanaka; Brady Rumph; Daniel Bolliger; Jerrold H. Levy

doi:10.1160/TH09-09-0632

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2010; 103(04): 863-865
DOI: 10.1160/TH09-09-0632

Letters to the Editor

Schattauer GmbH

In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition

Fania Szlam

¹Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia, USA

,

Kenichi A. Tanaka

¹Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia, USA

,

Brady Rumph

¹Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia, USA

,

Daniel Bolliger

²Department of Anesthesiology, University of Basel Hospital, Basel, Switzerland

,

Jerrold H. Levy

¹Department of Anesthesiology Emory University School of Medicine, Atlanta, Georgia, USA

References
1 Serebruany VL, Malinin AI, Atar D. et al. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. Am Heart J 2007; 153: 371-377.
2 Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 07: 651-657.
3 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
4 Altman R, Scazziota A, De Lourdes Herrera M. et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 04: 2022-2027.
5 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
6 Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996; 81: 533-543.
7 Armstrong P, Dhanji A, Truss N. et al. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009; 102: 772-778.
8 Ferreiro JL, DJ A. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
9 Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005; 112: 2725-2734.
10 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
11 Mayer SA, Schwab S. Advances in critical care and emergency medicine 2007. Stroke 2008; 39: 261-263.
12 Romagnoli S, Bevilacqua S, Gelsomino S. et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102: 1320-1326.
13 Bal Dit Sollier C, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101: 116-122.
14 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009; 101: 108-115.
15 Serebruany V, Shalito I, Kopyleva O. Prasugrel development – claims and achievements. Thromb Haemost 2009; 101: 14-22.